• Explore /
  • Poster
  • / Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.

Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.

Abstract Poster

Authors

John Powderly, II

John D. Powderly

Carolina BioOncology Institute, Huntersville, NC

John D. Powderly , Ryan J. Sullivan , Martin Gutierrez , Adnan Khattak , Sajeve Samuel Thomas , Antonio Jimeno , Stephanie Pascarella , Lili Zhu , Manju Morrissey , Robert S. Meehan , Ferdous Barlaskar , Michelle Brown , David R. Spigel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT05533697

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS2676)

DOI

10.1200/JCO.2023.41.16_suppl.TPS2676

Abstract #

TPS2676

Poster Bd #

511b

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Julio Antonio Peguero

First Author: Amita Patnaik

First Author: Zev A. Wainberg